0001493152-24-018436 | 10-Q | XBRL Viewer

Print Document

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferrred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	26,996,740	26,788,986
Common stock, shares outstanding	26,996,740	26,788,986
Treasury stock, shares	433,333	433,333

LEASE LIABILITIES	3 Months Ended
Mar. 31, 2024
Lease Liabilities
LEASE LIABILITIES	NOTE 7 – LEASE LIABILITIES *Operating Leases* The Company accounts for leases in accordance with ASC 842, which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. In July 2018, the Company entered into a long-term non-cancellable lease agreement for its manufacturing facility that requires aggregate average monthly payments of $10 beginning October 2018. The lease terminated in September 2023, with a Company option to extend for an additional five years. The Company classified the lease as an operating lease and determined that the value of the right of use asset and lease liability at the adoption date was $518 and $519, respectively, using a discount rate of 4.00%. Effective April 2022, the Company extended the lease for the additional five-year period, through September 2028, with no changes to any of the other terms of the lease and has the option to extend the lease for an additional five years. Prior to the extension, the remaining lease liability amounted to $174. On the date of the extension, the Company determined that the value of the new right of use asset and lease liability was $860, respectively, using a discount rate of 4.00%. As such, the Company recorded an increase in lease liability of $686 as a result of the lease extension. Effective July 2023, the Company extended the lease for an additional two-year period, through October 2030, with no changes to any of the other terms of the lease and has the option to extend the lease for an additional five years. Prior to the extension through October 2030, the remaining lease liability amounted to $701. On the date of the extension, the Company determined that the value of the new right of use asset and lease liability was $909, respectively, using a discount rate of 7.00%. As such, the Company recorded an increase in the lease liability of $208 as a result of the lease extension. In December 2020, the Company entered into a long-term non-cancellable lease agreement for a laboratory facility that requires aggregate average monthly payments of $18 beginning January 2021. The Company classified the lease as an operating lease and determined that the value of the right of use asset and lease liability at the adoption date was $439, respectively, using a discount rate of 4.00%. Effective February 2023, the Company extended the lease through December 2024, with no changes to any of the other terms of the lease. The average monthly rent payment on the extended lease is approximately $30 per month. Prior to the extension, the remaining lease liability amounted to $12. On the date of the extension, the Company determined that the value of the new right of use asset and lease liability was $649, respectively, using a discount rate of 5.5%. As such, the Company recorded an increase in the lease liability of $637 as a result of the lease extension. In July 2021, the Company entered into a long-term non-cancellable lease agreement for its new corporate headquarters that requires aggregate average monthly payments of $10 beginning August 2021. The lease terminates in July 2027. The Company classified the lease as an operating lease and determined that the value of the right of use asset and lease liability at the adoption date was $656, respectively, using a discount rate of 4.00%. In November 2023, the Company entered into a long-term non-cancellable lease agreement for a second manufacturing facility that requires aggregate average monthly payments of $12 beginning November 2023. The lease terminates in October 2030, with a Company option to extend for an additional five years. The Company classified the lease as an operating lease and determined that the value of the right of use asset and lease liability at the adoption date was $803, respectively, using a discount rate of 7.00%. During the three months ended March 31, 2024 and 2023, the Company made combined aggregate payments of $148 and $114, respectively, towards the lease liabilities. As of March 31, 2024 and December 31, 2023, the combined lease liability amounted to $2,371 and $2,519, respectively. ASC 842 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. During the three months ended March 31, 2024 and 2023, the Company reflected combined amortization of the right of use assets of $164 and $118, respectively, related to the leases, resulting in a combined net asset balance of $2,264 and $2,428 as of March 31, 2024 and December 31, 2023, respectively. *Other Leases* In November 2019, the Company entered into a short-term lease agreement for one of its office facilities, which was subsequently extended until December 2022 and is currently on a month-to-month basis. Rent expense was $9 during the three months ended March 31, 2024 and 2023, respectively.

LEASE LIABILITIES

3 Months Ended

Mar. 31, 2024

Lease Liabilities

LEASE LIABILITIES

NOTE 7 – LEASE LIABILITIES

Operating Leases

The Company accounts for leases in accordance with ASC 842, which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. In July 2018, the Company entered into a long-term non-cancellable lease agreement for its manufacturing facility that requires aggregate average monthly payments of $10 beginning October 2018. The lease terminated in September 2023, with a Company option to extend for an additional five years. The Company classified the lease as an operating lease and determined that the value of the right of use asset and lease liability at the adoption date was $518 and $519, respectively, using a discount rate of 4.00%. Effective April 2022, the Company extended the lease for the additional five-year period, through September 2028, with no changes to any of the other terms of the lease and has the option to extend the lease for an additional five years. Prior to the extension, the remaining lease liability amounted to $174. On the date of the extension, the Company determined that the value of the new right of use asset and lease liability was $860, respectively, using a discount rate of 4.00%. As such, the Company recorded an increase in lease liability of $686 as a result of the lease extension. Effective July 2023, the Company extended the lease for an additional two-year period, through October 2030, with no changes to any of the other terms of the lease and has the option to extend the lease for an additional five years. Prior to the extension through October 2030, the remaining lease liability amounted to $701. On the date of the extension, the Company determined that the value of the new right of use asset and lease liability was $909, respectively, using a discount rate of 7.00%. As such, the Company recorded an increase in the lease liability of $208 as a result of the lease extension.

In December 2020, the Company entered into a long-term non-cancellable lease agreement for a laboratory facility that requires aggregate average monthly payments of $18 beginning January 2021. The Company classified the lease as an operating lease and determined that the value of the right of use asset and lease liability at the adoption date was $439, respectively, using a discount rate of 4.00%. Effective February 2023, the Company extended the lease through December 2024, with no changes to any of the other terms of the lease.

The average monthly rent payment on the extended lease is approximately $30 per month. Prior to the extension, the remaining lease liability amounted to $12. On the date of the extension, the Company determined that the value of the new right of use asset and lease liability was $649, respectively, using a discount rate of 5.5%. As such, the Company recorded an increase in the lease liability of $637 as a result of the lease extension.

In July 2021, the Company entered into a long-term non-cancellable lease agreement for its new corporate headquarters that requires aggregate average monthly payments of $10 beginning August 2021. The lease terminates in July 2027. The Company classified the lease as an operating lease and determined that the value of the right of use asset and lease liability at the adoption date was $656, respectively, using a discount rate of 4.00%.

In November 2023, the Company entered into a long-term non-cancellable lease agreement for a second manufacturing facility that requires aggregate average monthly payments of $12 beginning November 2023. The lease terminates in October 2030, with a Company option to extend for an additional five years. The Company classified the lease as an operating lease and determined that the value of the right of use asset and lease liability at the adoption date was $803, respectively, using a discount rate of 7.00%.

During the three months ended March 31, 2024 and 2023, the Company made combined aggregate payments of $148 and $114, respectively, towards the lease liabilities. As of March 31, 2024 and December 31, 2023, the combined lease liability amounted to $2,371 and $2,519, respectively.

ASC 842 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. During the three months ended March 31, 2024 and 2023, the Company reflected combined amortization of the right of use assets of $164 and $118, respectively, related to the leases, resulting in a combined net asset balance of $2,264 and $2,428 as of March 31, 2024 and December 31, 2023, respectively.

Other Leases

In November 2019, the Company entered into a short-term lease agreement for one of its office facilities, which was subsequently extended until December 2022 and is currently on a month-to-month basis. Rent expense was $9 during the three months ended March 31, 2024 and 2023, respectively.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES

The potentially dilutive securities consisted of the following:

	March 31, 2024		March 31, 2023
Stock options		5,118,920		4,201,019
Stock warrants		397,975		1,034,979
Restricted stock units		57,323		113,500
Stock warrants, issuable upon conversion of notes payable		-		69,893
Total		5,574,218		5,419,391

SCHEDULE OF AVAILABLE FOR SALE INVESTMENTS (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Marketable Securities [Line Items]
Amortized Cost	$ 15,573
Gross Unrealized Gains
Gross Unrealized Losses	(7)
Credit Losses
Fair Value	15,566
US Government Agencies Debt Securities [Member]
Marketable Securities [Line Items]
Amortized Cost	7,940
Gross Unrealized Gains
Gross Unrealized Losses	(4)
Credit Losses
Fair Value	7,936
US Treasury Securities [Member]
Marketable Securities [Line Items]
Amortized Cost	7,633
Gross Unrealized Gains
Gross Unrealized Losses	(3)
Credit Losses
Fair Value	$ 7,630

SCHEDULE OF STOCK OPTION ACTIVITY (Details)	3 Months Ended
SCHEDULE OF STOCK OPTION ACTIVITY (Details)	Mar. 31, 2024 $ / shares shares
Number of options shares, beginning \| shares	5,118,920
Weighted average exercise price, beginning	$ 9.76
Number of options shares, granted \| shares
Weighted average exercise price, granted
Number of options shares, cancelled \| shares
Exercise price range, cancelled
Weighted average exercise price, cancelled
Number of options shares, exercised \| shares
Exercise price range, exercised
Weighted average exercise price, exercised
Number of options shares, expired \| shares
Exercise price range, expired
Weighted average exercise price, expired
Number of options shares, ending \| shares	5,118,920
Weighted average exercise price, ending	$ 9.76
Number of options shares, vested and exercisable \| shares	3,855,160
Weighted average exercise price, vested and exercisable	$ 6.09
Number of options shares, unvested \| shares	1,263,760
Weighted average exercise price, unvested	$ 20.91
Minimum [Member]
Exercise price range, beginning	6.00
Exercise price range, granted
Exercise price range, ending	6.00
Exercise price range, vested and exercisable	6.00
Exercise price range, unvested	6.00
Maximum [Member]
Exercise price range, beginning	24.75
Exercise price range, ending	24.75
Exercise price range, vested and exercisable	10.50
Exercise price range, unvested	$ 24.75

LEASE LIABILITIES (Details Narrative) - USD ($) $ in Thousands		1 Months Ended						3 Months Ended
	Jul. 31, 2023	Nov. 30, 2023	Feb. 28, 2023	Apr. 30, 2022	Jul. 31, 2021	Dec. 31, 2020	Jul. 31, 2018	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Aggregate average monthly payments		$ 12	$ 30		$ 10	$ 18	$ 10
Option to extend lease	extended the lease for an additional two-year period, through October 2030, with no changes to any of the other terms of the lease and has the option to extend the lease for an additional five years. Prior to the extension through October 2030, the remaining lease liability amounted to $701	extend for an additional five years	extended the lease through December 2024, with no changes to any of the other terms of the lease.	the option to extend the lease for an additional five years			option to extend for an additional five years
Operating lease right of use asset								$ 2,264		$ 2,428
Operating lease liability	$ 909	$ 803	$ 649	$ 860	$ 656	$ 12	$ 174	2,371		$ 2,519
Operating lease discount rate	7.00%	7.00%	5.50%	4.00%	4.00%	4.00%	4.00%
Increase in lease liability	$ 208		$ 637	$ 686				(148)	$ (114)
Payment for operating lease								148	114
Right of use assets								164	118
Rent expense								$ 9	$ 9
Accounting Standards Update 2016-02 [Member]
Operating lease right of use asset							$ 518
Operating lease liability						$ 439	$ 519

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Use of Estimates

Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates.

Income (Loss) Per Share

Income (Loss) Per Share

Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued.

For the three months ended March 31, 2024 and 2023, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive.

The potentially dilutive securities consisted of the following:

	March 31, 2024		March 31, 2023
Stock options		5,118,920		4,201,019
Stock warrants		397,975		1,034,979
Restricted stock units		57,323		113,500
Stock warrants, issuable upon conversion of notes payable		-		69,893
Total		5,574,218		5,419,391

Revenue Recognition

Revenue Recognition

The Company records revenue under the guidance of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606) which requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services.

The Company determines revenue recognition through the following steps:

	●	Identification of the contract, or contracts, with a customer

	●	Identification of the performance obligations in the contract

	●	Determination of the transaction price

	●	Allocation of the transaction price to the performance obligations in the contract

	●	Recognition of revenue when, or as, the Company satisfies a performance obligation.

Under certain of the Company’s licensing, supply and collaboration agreements, it is entitled to receive payment upon the achievement of contingent milestone events or the performance of obligations. The Company recognizes revenue based on guidance in ASC 606. In evaluating revenue recognition under a license agreement, the Company uses a two-step process for determining whether a promised good or service (including a license of intellectual property) is distinct and, therefore, is a performance obligation: (1) consideration of the individual good or service (i.e., whether the good or service is capable of being distinct); and (2) consideration of whether the good or service is separately identifiable from other promises in the contract (i.e., whether the promise to transfer the good or service is distinct in the context of the contract). Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the Company’s balance sheet. Amounts expected to be recognized as revenue in the next 12 months following the balance sheet date are classified as current liabilities.

During the three months ended March 31, 2024, the Company recognized revenue of $8 relating to its license agreement with ELIAS Animal Health, LLC.

Cash Equivalents

Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less at date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of March 31, 2024 and December 31, 2023. As of March 31, 2024 and December 31, 2023, the amount of cash equivalents included in cash and cash equivalents totaled $2,988 and $7,924, respectively.

Short-Term Investments

Short-Term Investments

The Company’s short-term debt security investments are classified as available-for-sale and are carried at fair value, with the unrealized gains and non-credit related losses reported as a component of accumulated other comprehensive loss and included in stockholders’ equity. Realized gains and losses and declines in value determined to be other than temporary are based on the specific identification method and are included as a component of total other income (expense), net in the Statements of Operations. There were no realized gains or losses during the three months ended March 31, 2024.

For available-for-sale securities in an unrealized loss position, the Company first assesses whether it intends to sell, or if it is more likely than not that it will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through a charge to interest income. For available-for-sale securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers such factors as, among other things, the severity of the impairment, any changes in interest rates, how long the market value of the investment has been less than its original cost, the Company’s ability and intent to retain the short-term debt security investment for a period of time sufficient to allow for any anticipated recovery in fair value and market conditions in general. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive loss on the statements of operations and comprehensive loss.

No credit-related losses or impairments have been recognized on the Company’s investments in available-for-sale securities during the three months ended March 31, 2024.

All of the Company’s short-term investments as of March 31, 2024 had maturities of less than one year.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value:

	●	Level 1 — Quoted prices in active markets for identical assets or liabilities.

	●	Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

	●	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s short-term investments and cash equivalents are carried at fair value, determined according to the fair value hierarchy described in Note 3 below. The carrying amounts of financial instruments such as cash, short-term investments, and accounts payable and accrued liabilities, approximate the related fair values due to the short-term maturities of these instruments.

Stock-Based Compensation

Stock-Based Compensation

The Company measures all stock options and other stock-based awards granted based on the fair value of the award on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is recognized in the period of the forfeiture. Generally, the Company issues stock options with only service-based vesting conditions and records the expense for these awards using the straight-line method over the requisite service period.

The Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified.

The Company was a private company until the completion of its IPO on January 30, 2023. In 2022 and prior, the Company estimated the fair value of common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, guideline public company information, the prices at which the Company sold its common stock to third parties in arms’ length transactions, the rights and preferences of securities senior to the Company’s common stock at the time, and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options at each valuation date, as applicable.

The fair value of each stock option grant is estimated using the Black-Scholes option-pricing model. The Company was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics similar to the Company. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero, based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.

Comprehensive Loss

Comprehensive Loss

Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with shareholders. For the three months ended March 31, 2024, comprehensive loss included $19 of unrealized losses on short-term investments, net of tax.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expense categories that are regularly provided to the chief operating decision maker and included in each reported measure of a segment’s profit or loss. The update also requires all annual disclosures about a reportable segment’s profit or loss and assets to be provided in interim periods and for entities with a single reportable segment to provide all the disclosures required by ASC 280, Segment Reporting, including the significant segment expense disclosures. The Company adopted ASU 2023-07 beginning January 1, 2024. The Company does not believe the impact of the new guidance and related codification improvements had a material impact to its financial position, results of operations and cash flows.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 8	$ 170
Operating expenses:
Research and development	4,010	2,845
General and administrative	4,113	3,787
Total operating expenses	8,123	6,632
Loss from operations	(8,115)	(6,462)
Other income (expenses):
Interest income	265
Interest expense		(143)
Debt discount amortization		(649)
Financing costs		(3,110)
Total other income (expenses), net	265	(3,902)
NET LOSS	$ (7,850)	$ (10,364)
LOSS PER COMMON SHARE - BASIC	$ (0.29)	$ (0.53)
LOSS PER COMMON SHARE - DILUTED	$ (0.29)	$ (0.53)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - BASIC	26,849,737	19,575,631
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING - DILUTED	26,849,737	19,575,631

SHAREHOLDERS’ EQUITY

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

SHAREHOLDERS’ EQUITY

NOTE 8 - SHAREHOLDERS’ EQUITY

Common Stock

Authorized shares

The Company’s Certificate of Incorporation authorizes the Company to issue up to 200,000,000 of its common shares. Holders of shares of common stock have full voting rights, one vote for each share held of record. Shareholders are entitled to receive dividends as may be declared by the Company’s board of directors (the “Board”) out of funds legally available therefore and share pro rata in any distributions to shareholders upon liquidation. Shareholders have no conversion, pre-emptive or subscription rights. All outstanding shares of common stock are fully paid and non-assessable. As of March 31, 2024 and December 31, 2023, there were 26,996,740 and 26,788,986 shares of common stock issued and outstanding, respectively.

Common Stock Issued for Cash Upon Closing of the Company’s Private Placements

In May and June 2023, the Company entered into securities purchase agreements (the “Purchase Agreements”) with certain investors pursuant to which the Company agreed to sell and issue shares of its common stock in two private placement transactions. The Company agreed to extend certain commitments under the Purchase Agreement totaling $24,000 past their initial due dates.

In November 2023, the Company agreed to extend the funding deadline for $2,000 of the remaining aggregate investment amounts to March 31, 2024. The investor who was obligated to fund $22,000 of the remaining committed investment amounts has not made such payments and has indicated that he does not intend to comply with his investment commitments under the Purchase Agreements. The Company is currently evaluating its potential remedies with respect to this investor’s non-compliance with his contractual obligations to the Company.

Grant of Restricted Stock Units (RSU)

The following table summarizes restricted common stock activity during the three months ended March 31, 2024:

	Number of Restricted Shares			Fair Value			Weighted Average Grant Date Fair Value
Non-vested, December 31, 2023		57,900		$	1,103		$	22.40
Granted		130,690			852			6.52
Vested		(131,267	)		(989	)		7.53
Forfeited		—			—			—
Non-vested, March 31, 2024		57,323		$	966		$	16.85

During the three months ended March 31, 2024, the Board approved the issuance of a combined total of 130,690 restricted shares of the Company’s common stock to certain of its employees. The fair value of the shares on the date of grant was $852 and was recorded during the three months ended March 31, 2024. The restricted common stock was granted under the Company’s 2022 Equity Incentive Plan (“the 2022 Plan”). All of these shares, plus an additional 577 restricted shares, vested during the three months ended March 31, 2024.

During the three months ended March 31, 2024, the Company recorded $989 of stock compensation for the fair value vesting of restricted common stock. As of March 31, 2024, $966 of unamortized compensation remained.

Stock Options

In August 2009, the Board approved the adoption of the 2009 Equity Incentive Plan (“the 2009 Plan”). The 2009 Plan was initiated to encourage and enable employees, directors and consultants of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 6,166,666 of the authorized shares of the Company’s common stock may be subject to, or issued pursuant to, the terms of the plan. As of March 31, 2024, no shares were available for grant under the 2009 plan.

In September 2018, the Board approved the adoption of the 2019 Equity Incentive Plan (“the 2019 Plan”). The 2019 Plan was initiated to encourage and enable employees, directors and consultants of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. The 2019 Plan allows for the following types of awards: (i) incentive stock options (“ISOs”); (ii) nonstatutory stock options (“NSOs”); (iii) stock appreciation rights; (iv) restricted stock awards; (v) restricted stock unit awards (“RSUs”); (vi) other stock awards. The maximum number of shares of our common stock that may be issued under our 2019 Plan is 2,059,073 shares. Outstanding stock awards granted under the 2009 Plan that (i) expire or terminate for any reason prior to exercise or settlement; (ii) are forfeited because of failure to meet a contingency or condition required to vest such shares or otherwise return to us; or (iii) are required or withheld (or not issued) to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award can be added to the authorized shares as returning shares, not to exceed 3,774,260 shares. The maximum number of shares of our common stock under our 2019 Plan that may be issued is 5,833,333 shares. As of March 31, 2024, a total of 1,632,314 shares were available for grant under the 2019 plan.

In June 2022, the Board approved the adoption of the 2022 Plan. The 2022 Plan provides for the grant of ISOs to employees, including employees of any parent or subsidiary, and for the grant of NSOs, stock appreciation rights, restricted stock awards, RSUs, performance awards and other forms of stock awards to employees, directors, and consultants, including employees and consultants of our affiliates. The 2022 Plan is a successor to the 2019 Plan. No further grants will be made under the 2019 Plan. The maximum number of shares of the Company’s common stock under the 2022 Plan that may be issued is 2,800,000 shares. In addition, the number of shares of the Company’s common stock reserved for issuance under the 2022 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2024 and continuing through and including January 1, 2032, in an amount equal to 5% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Board. During the three months ended March 31, 2024, no option shares were granted under the 2022 Plan. As of December 31, 2023, a total of 1,922,212 shares were available for grant under the 2022 plan. In January 2024, the number of shares available to be issued under the 2022 Plan automatically increased by 1,339,449 shares, as determined by the Plan, and 3,261,661 shares were available for grant under the 2022 Plan as of March 31, 2024.

In September 2023, the Board approved the adoption of the Company’s 2023 Inducement Plan (the “Inducement Plan”) to reserve 1,000,000 shares of the Company’s common stock to be used exclusively for grants of awards to individuals that were not previously employees or directors of the Company as an inducement material to the individual’s entry into employment with the Company. The Inducement Plan provides for the grant of NSOs, stock appreciation rights, restricted stock awards, RSUs, performance-based cash and stock awards, and other stock-based awards. In addition, forms of (i) Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise and (ii) Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement, for both (a) executive officers and (b) employees at or below the vice president level, were adopted and approved for use with the Inducement Plan. The terms and conditions of the Inducement Plan are substantially similar to the Company’s stockholder-approved 2022 Plan. During the three months ended March 31, 2024, no awards were granted under the Inducement Plan. As of March 31, 2024, a total of 555,700 shares were available for grant under the Inducement plan.

Option exercise prices are set forth in the grant notice, without commission or other charge, provided however, that the price per share of the shares subject to the option shall not be less than the greater of (i) 100% of the fair market value of a share of stock on the grant date, or (ii) 110% of the fair market value of a share of stock on the grant date in the case of a Participant then owning more than 10% of the total combined voting power of all classes of stock of the Company or any “subsidiary corporation” of the Company or any “parent corporation” of the Company. Options to employees, directors and consultants generally vest and become exercisable over a period not exceeding four years. Options typically expire ten years after date of grant.

The Company’s policy is to recognize compensation cost for awards with only service conditions on a straight- line basis over the requisite service period for the entire award. Additionally, the Company’s policy is to issue new shares of common stock to satisfy stock option exercises. The Company applied fair value accounting for all share-based payments awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model.

The table below summarizes the Company’s stock option activities for the three months ended March 31, 2024:

SCHEDULE OF STOCK OPTION ACTIVITY

	Number of Option Shares		Exercise Price Range Per Share		Weighted Average Exercise Price
Balance, December 31, 2023		5,118,920	$	6.00 - 24.75	$	9.76
Granted		—		—		—
Cancelled		—		—		—
Exercised		—		—		—
Expired		—		—		—
Balance, March 31, 2024		5,118,920	$	6.00 - 24.75	$	9.76
Vested and exercisable, March 31, 2024		3,855,160	$	6.00 - 10.50	$	6.09
Unvested, March 31, 2024		1,263,760	$	6.00 – 24.75	$	20.91

The following table summarizes information concerning outstanding and exercisable options as of March 31, 2024:

		Options Outstanding						Options Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price
$	6.00		3,878,133		4.30	$	6.00		3,763,653		4.20	$	6.00
	6.01 – 10.50		90,099		1.78		9.52		90,099		1.78		9.52
	10.51 – 24.75		1,150,688		9.45		22.26		1,408		9.44		22.40
$	6.00 - 24.75		5,118,920		5.43	$	9.76		3,855,160		4.14	$	6.09

During the three months ended March 31, 2024, the Company extended the option term for two option holders for an additional year through December 31, 2024. The total number of shares that were extended was 51,581 shares. The cost of the stock option modifications was $303 and was recorded during the three months ended March 31, 2024. In September 2022, the Board approved a stock option repricing whereby the exercise price of previously granted and unexercised options held by certain employees, directors and key advisers with exercise prices between $9.00 and $10.50 per share, would be adjusted to $6.00 per share, the closing price of the Company’s initial public offering. The total cost of the repricing was $2,733, of which $2,689 was recorded as of December 31, 2023, and $11 was recorded during the three months ended March 31, 2024. The remainder of the cost will be recorded over the future vesting periods of the options.

During the three months ended March 31, 2024, the Company recorded $1,489 of stock compensation for the value of all options vesting during the period. As of March 31, 2024, unvested compensation of $18,090 remained that will be amortized over the remaining vesting period, through September 2027. The aggregate intrinsic value for option shares outstanding at March 31, 2024 was $1,645.

At the time of the issuances of stock options, the Company believed the Company’s estimates of the fair value for financial reporting purposes of the Company’s common stock were reasonable and consistent with the Company’s understanding of how similarly situated companies in the industry were valued.

Stock Warrants

The table below summarizes the Company’s warrants activities for the three months ended March 31, 2024:

SCHEDULE OF WARRANTS ACTIVITY

	Number of Warrant Shares			Exercise Price Range Per Share		Weighted Average Exercise Price
Balance, December 31, 2023		512,759		$	3.00 - 10.50	$	7.14
Granted		—			—		—
Cancelled		—			—		—
Exercised		(76,487	)		9.00		9.00
Expired		(38,297	)		9.00 - 10.50		9.15
Balance, March 31, 2024		397,975		$	3.00 - 9.00	$	6.59
Vested and exercisable, March 31, 2024		397,975		$	3.00 - 9.00	$	6.59

The following table summarizes information concerning outstanding and exercisable warrants as of March 31, 2024:

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price
$	3.00		133,333		2.92	$	3.00		133,333		2.92	$	3.00
	3.01 – 9.00		264,642		2.89		8.40		264,642		2.89		8.40

$	3.00 – 9.00		397,975		2.90	$	6.59		397,975		2.90	$	6.59

During the three months ended March 31, 2024, warrant holders exercised 76,487 warrant shares at an exercise price of $9.00 per share for proceeds of $688.

The aggregate intrinsic value for warrant shares outstanding at March 31, 2024 was $457.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS (Details) - $ / shares	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants Outstanding number of outstanding	397,975	512,759
Warrants outstaning weighted average exercise price	$ 6.59	$ 7.14
Warrants exercisable number of outstanding	397,975
Warrants exercisable weighted average exercise price	$ 6.59
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 3.00
Warrants Outstanding number of outstanding	133,333
Warrants outstanding average remaining contractual life	2 years 11 months 1 day
Warrants outstaning weighted average exercise price	$ 3.00
Warrants exercisable number of outstanding	133,333
Warrants exercisable average remaining contractual life	2 years 11 months 1 day
Warrants exercisable weighted average exercise price	$ 3.00
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 9.00
Warrants Outstanding number of outstanding	264,642
Warrants outstanding average remaining contractual life	2 years 10 months 20 days
Warrants outstaning weighted average exercise price	$ 8.40
Warrants exercisable number of outstanding	264,642
Warrants exercisable average remaining contractual life	2 years 10 months 20 days
Warrants exercisable weighted average exercise price	$ 8.40
Range of exercise prices, lower limit	3.01
Exercise Price Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 9.00
Warrants Outstanding number of outstanding	397,975
Warrants outstanding average remaining contractual life	2 years 10 months 24 days
Warrants outstaning weighted average exercise price	$ 6.59
Warrants exercisable number of outstanding	397,975
Warrants exercisable average remaining contractual life	2 years 10 months 24 days
Warrants exercisable weighted average exercise price	$ 6.59
Range of exercise prices, lower limit	$ 3.00

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Flows from Operating Activities
Net loss	$ (7,850)	$ (10,364)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	84	136
Net amortization of premiums and discounts on short-term investments	(151)
Right-of-use assets	164	118
Amortization of debt discount		649
Stock compensation	1,489	227
Fair value of restricted stock units	989	198
Cost of stock option modifications and repricing	314	2,606
Fair value of warrants issued in connection with the conversion of convertible notes payable		3,110
(Increase) Decrease in:
Prepaid expenses and other assets	(565)	(223)
(Decrease) Increase in:
Accounts payable and accrued expenses	1,529	(913)
Accrued payroll and payroll taxes	(209)	58
Accrued interest payable		92
Deferred revenue		(170)
Lease liability	(148)	(114)
Net cash used in operating activities	(4,354)	(4,590)
Cash Flows from Investing Activities
Purchases of property and equipment	(30)	(109)
Purchase of short-term investments	(3,161)
Proceeds from sales and maturities of short-term investments	1,500
Net cash used in investing activities	(1,691)	(109)
Cash Flows from Financing Activities
Proceeds from notes payable - shareholders		900
Repayment of notes payable - shareholders		(460)
Payment of deferred offering costs		(303)
Proceeds from the exercise of stock warrants	688
Proceeds from common stock issued for cash in connection with the closing of the IPO		14,503
Net cash provided by financing activities	688	14,640
Net increase (decrease) in cash and cash equivalents	(5,357)	9,941
Cash and cash equivalents at beginning of period	9,418	397
Cash and cash equivalents at end of period	4,061	10,338
Supplemental cash flows disclosures:
Interest paid		50
Taxes paid
Supplemental non-cash financing disclosures:
Effect of the extension of right-of-use assets and operating leases		649
Reclassification of deferred offering costs to shareholders’ equity		1,871
Reclassification of warrant liabilities to shareholders’ equity		169
Conversion of convertible notes payable, accrued interest and loan fees to shareholders’ equity		29,896
Conversion of preferred stock to common stock		22
Conversion of dividends payable to shareholders’ equity		3,443
Conversion of notes payable-shareholders and accrued interest to shareholders’ equity

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2024

Property, Plant and Equipment [Abstract]

SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF PROPERTY AND EQUIPMENT

	March 31, 2024			December 31, 2023
Furniture and office equipment	$	148		$	148
Laboratory equipment		2,819			2,792
Computer equipment		127			127
Leasehold improvements		557			557
Construction-in-progress		998			995
Property and equipment, gross		4,649			4,619
Less: accumulated depreciation and amortization		(3,533	)		(3,449	)
Property and equipment, net	$	1,116		$	1,170

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation	$ 84	$ 136
Facility design services			$ 995
Design services	$ 3

FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

SCHEDULE OF FINANCIAL ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS

The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis:

	Fair Value Measurements as of March 31, 2024, Using:
	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	2,988	$	—	$	—	$	2,988
Short-term investments:
U.S. Government Agency bonds		—		7,936		—		7,936
U.S. Treasury bonds		—		7,630		—		7,630
	$	2,988	$	15,566	$	—	$	18,554

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

Income (Loss) Per Share

For the three months ended March 31, 2024 and 2023, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive.

The potentially dilutive securities consisted of the following:

	March 31, 2024		March 31, 2023
Stock options		5,118,920		4,201,019
Stock warrants		397,975		1,034,979
Restricted stock units		57,323		113,500
Stock warrants, issuable upon conversion of notes payable		-		69,893
Total		5,574,218		5,419,391

Revenue Recognition

The Company determines revenue recognition through the following steps:

	●	Identification of the contract, or contracts, with a customer

	●	Identification of the performance obligations in the contract

	●	Determination of the transaction price

	●	Allocation of the transaction price to the performance obligations in the contract

	●	Recognition of revenue when, or as, the Company satisfies a performance obligation.

During the three months ended March 31, 2024, the Company recognized revenue of $8 relating to its license agreement with ELIAS Animal Health, LLC.

Cash Equivalents

Short-Term Investments

No credit-related losses or impairments have been recognized on the Company’s investments in available-for-sale securities during the three months ended March 31, 2024.

All of the Company’s short-term investments as of March 31, 2024 had maturities of less than one year.

Fair Value of Financial Instruments

	●	Level 1 — Quoted prices in active markets for identical assets or liabilities.

	●	Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

	●	Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Stock-Based Compensation

Comprehensive Loss

Recent Accounting Pronouncements

LEGAL MATTERS

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

LEGAL MATTERS

NOTE 9 - LEGAL MATTERS

As of December 31, 2023, the Company was the defendant in one pending litigation. On November 6, 2023, the Los Angeles County Superior Court granted the Company’s motion for summary judgment and issued an order and final judgment dismissing all claims against the Company with prejudice. Although the plaintiff filed a notice of appeal of the dismissal order with the California Court of Appeal, the plaintiff subsequently filed a request for dismissal of his appeal, which was dismissed by the appellate court on February 23, 2024. Accordingly, the order and final judgment dismissing all claims against the Company with prejudice is now final.

In the future, the Company may be involved in additional actual and/or threatened legal proceedings, claims, investigations and government inquiries arising in the ordinary course of our business, including legal proceedings, claims, investigations and government inquiries involving intellectual property, data privacy and security, other torts, illegal or objectionable content, consumer protection, securities, employment, contractual rights, civil rights infringement, false or misleading advertising, or other legal claims relating to our business.

SHAREHOLDERS’ EQUITY (Tables)

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY

The following table summarizes restricted common stock activity during the three months ended March 31, 2024:

	Number of Restricted Shares			Fair Value			Weighted Average Grant Date Fair Value
Non-vested, December 31, 2023		57,900		$	1,103		$	22.40
Granted		130,690			852			6.52
Vested		(131,267	)		(989	)		7.53
Forfeited		—			—			—
Non-vested, March 31, 2024		57,323		$	966		$	16.85

SCHEDULE OF STOCK OPTION ACTIVITY

The table below summarizes the Company’s stock option activities for the three months ended March 31, 2024:

SCHEDULE OF STOCK OPTION ACTIVITY

	Number of Option Shares		Exercise Price Range Per Share		Weighted Average Exercise Price
Balance, December 31, 2023		5,118,920	$	6.00 - 24.75	$	9.76
Granted		—		—		—
Cancelled		—		—		—
Exercised		—		—		—
Expired		—		—		—
Balance, March 31, 2024		5,118,920	$	6.00 - 24.75	$	9.76
Vested and exercisable, March 31, 2024		3,855,160	$	6.00 - 10.50	$	6.09
Unvested, March 31, 2024		1,263,760	$	6.00 – 24.75	$	20.91

SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS

The following table summarizes information concerning outstanding and exercisable options as of March 31, 2024:

		Options Outstanding						Options Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price
$	6.00		3,878,133		4.30	$	6.00		3,763,653		4.20	$	6.00
	6.01 – 10.50		90,099		1.78		9.52		90,099		1.78		9.52
	10.51 – 24.75		1,150,688		9.45		22.26		1,408		9.44		22.40
$	6.00 - 24.75		5,118,920		5.43	$	9.76		3,855,160		4.14	$	6.09

SCHEDULE OF WARRANTS ACTIVITY

The table below summarizes the Company’s warrants activities for the three months ended March 31, 2024:

SCHEDULE OF WARRANTS ACTIVITY

	Number of Warrant Shares			Exercise Price Range Per Share		Weighted Average Exercise Price
Balance, December 31, 2023		512,759		$	3.00 - 10.50	$	7.14
Granted		—			—		—
Cancelled		—			—		—
Exercised		(76,487	)		9.00		9.00
Expired		(38,297	)		9.00 - 10.50		9.15
Balance, March 31, 2024		397,975		$	3.00 - 9.00	$	6.59
Vested and exercisable, March 31, 2024		397,975		$	3.00 - 9.00	$	6.59

SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS

The following table summarizes information concerning outstanding and exercisable warrants as of March 31, 2024:

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price
$	3.00		133,333		2.92	$	3.00		133,333		2.92	$	3.00
	3.01 – 9.00		264,642		2.89		8.40		264,642		2.89		8.40

$	3.00 – 9.00		397,975		2.90	$	6.59		397,975		2.90	$	6.59

PROPERTY AND EQUIPMENT

3 Months Ended

Mar. 31, 2024

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 5 - PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at March 31, 2024 and December 31, 2023:

SCHEDULE OF PROPERTY AND EQUIPMENT

	March 31, 2024			December 31, 2023
Furniture and office equipment	$	148		$	148
Laboratory equipment		2,819			2,792
Computer equipment		127			127
Leasehold improvements		557			557
Construction-in-progress		998			995
Property and equipment, gross		4,649			4,619
Less: accumulated depreciation and amortization		(3,533	)		(3,449	)
Property and equipment, net	$	1,116		$	1,170

Depreciation expense for the three months ended March 31, 2024 and 2023 was $84 and $136, respectively.

During the year ended December 31, 2023, the Company expended $995 on facility design services relating to future planned construction on its manufacturing facility. During the three months ended March 31, 2024, the Company expended an additional $3 on design services. The Company has accounted for the expenditures as construction-in-progress as of March 31, 2024 and December 31, 2023, and no depreciation will be recorded on these expenditures until the facility has been placed in service. The Company’s plan to complete the design phase and begin construction on the facility will be based on available financial resources.

SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended	12 Months Ended
SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($)	Sep. 30, 2018	Jun. 30, 2022	Sep. 30, 2018	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Jan. 31, 2024	Nov. 30, 2023	Sep. 30, 2023	Aug. 31, 2009
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized				200,000,000		200,000,000
Common stock, shares issued				26,996,740		26,788,986
Common stock, shares outstanding				26,996,740		26,788,986
Additional commitments received						$ 24,000,000
Issuance of restricted shares				130,690
Fair value granted				$ 852,000
Additional restricted shares, vested				131,267
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value				$ 989,000
Unamortized compensation				$ 966,000
Number of shares extended
Fair market value of shares percentage, description				(i) 100% of the fair market value of a share of stock on the grant date, or (ii) 110% of the fair market value of a share of stock on the grant date in the case of a Participant then owning more than 10% of the total combined voting power of all classes of stock of the Company or any “subsidiary corporation” of the Company or any “parent corporation” of the Company.
Cost of the stock option modification				$ 303,000
Repricing costs				2,733,000		$ 2,689,000
Stock vested				11,000
Share compensation				1,489,000
Unvested compensation				18,090,000
Aggregate intrinsic value outstanding				$ 1,645,000
Warrants to purchase shares				76,487
Common stock exercise price				$ 9.00
Proceeds from exercise of warrants				$ 688,000
Aggregate intrinsic value of warrants				$ 457,000
Exercise Price Range One [Member]
Subsidiary, Sale of Stock [Line Items]
Range of exercise prices, upper limit				$ 6.00
Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price range per share, expired				10.50
Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Exercise price range per share, expired				$ 9.00
2009 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock shares authorized										6,166,666
Additional shares authorized	3,774,260
2019 Equity Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Shares of common stock issued			2,059,073
Shares of common stock option granted				1,632,314
2019 Equity Incentive Plan [Member] \| Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Shares of common stock issued			5,833,333
2022 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Shares of common stock issued		2,800,000					1,339,449
Number of shares of common stock percentage		5.00%
2022 Plan [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Shares of common stock option granted						1,922,212	3,261,661
Number of shares extended				0
2023 Inducement Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Shares of common stock issued									1,000,000
2023 Inducement Plan [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Shares of common stock option granted				555,700
Fair value of stock option				$ 0
Two Option Holders [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares extended				51,581
Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Additional restricted shares, vested				577
Director [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of restricted shares				130,690
Fair value granted					$ 852,000
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Investments								$ 22,000,000
March Thirty One Two Thousand Twenty Four [Member]
Subsidiary, Sale of Stock [Line Items]
Investments								$ 2,000,000

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 4,649	$ 4,619
Less: accumulated depreciation and amortization	(3,533)	(3,449)
Property and equipment, net	1,116	1,170
Furniture and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	148	148
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,819	2,792
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	127	127
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	557	557
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 998	$ 995

BASIS OF PRESENTATION (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 7,850	$ 10,364
Cash used in operations	4,354	$ 4,590
Accumulated deficit	229,374		$ 221,524
Cash and cash equivalents and short-term investments	$ 19,627

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

SHORT-TERM INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2024

Investments, All Other Investments [Abstract]

SCHEDULE OF AVAILABLE FOR SALE INVESTMENTS

As of March 31, 2024, the Company’s available-for-sale investments by type, consisted of the following:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Credit Losses		Fair Value
U.S. Government Agency bonds	$	7,940	$	—	$	(4	)	$	—	$	7,936
U.S. Treasury bonds		7,633		—		(3	)		—		7,630
Total	$	15,573	$	—	$	(7	)	$	—	$	15,566

- Definition

Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

+ Details

ACCRUED PAYROLL AND PAYROLL TAXES

3 Months Ended

Mar. 31, 2024

Accrued Payroll And Payroll Taxes

ACCRUED PAYROLL AND PAYROLL TAXES

NOTE 6 – ACCRUED PAYROLL AND PAYROLL TAXES

As of December 31, 2023, a total of $2,117 was owed to the Company’s Chief Executive Officer and another employee for past due balances that had accrued over a several year period, and for current accrued payroll and payroll taxes, and other compensation related benefits, including payroll tax liabilities of $321 relating to stock option exercises and restricted stock unit vesting. During the three months ended March 31, 2024, the Company did not repay any of the past due accrued amounts owed to the employees, but did repay the $321 owed for payroll tax liabilities. As of March 31, 2024, a total of $1,908 was owed to employees for these past due balances, and for current accrued payroll and payroll taxes, and other compensation related benefits. Subsequent to March 31, 2024, the Company repaid $1,024 of the past due accrued amounts owed to employees.

SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
Equity [Abstract]
Number of restricted shares, beginning \| shares	57,900
Fair value, beginning \| $	$ 1,103
Weighted average grant date fair value, beginning \| $ / shares	$ 22.40
Number of restricted shares, granted \| shares	130,690
Fair value, granted \| $	$ 852
Weighted average grant date fair value, granted \| $ / shares	$ 6.52
Number of restricted shares, vested \| shares	(131,267)
Fair value, vested \| $	$ (989)
Weighted average grant date fair value, vested \| $ / shares	$ 7.53
Number of restricted shares, forfeited \| shares
Fair value, forfeited \| $
Weighted average grant date fair value, forfeited \| $ / shares
Number of restricted shares, ending \| shares	57,323
Fair value, ending \| $	$ 966
Weighted average grant date fair value, ending \| $ / shares	$ 16.85

BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

NOTE 1 – BASIS OF PRESENTATION

Organization and Operations

Genelux Corporation (“Genelux” or the “Company”), a Delaware Corporation, incorporated on September 4, 2001, is a late clinical-stage biopharmaceutical company located in Westlake Village, California. The Company is engaged in the research and development of diagnostic and therapeutic solutions for cancer for which there is no effective treatment today. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.

Basis of Presentation of Unaudited Financial Information

The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.

Going Concern

The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, the Company has experienced recurring losses from operations since inception and incurred a net loss of $7,850 and used cash in operations of $4,354 during the three months ended March 31, 2024, and had an accumulated deficit of $229,374 as of March 31, 2024. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

At March 31, 2024, the Company had cash and cash equivalents, and short-term investments, in the amount of $19,627. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, the Company has funded its operations primarily through equity and debt financings, and licensing income, and it expects to continue to rely on these sources of capital in the future.

No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in case of equity financing, or grant unfavorable terms in future licensing agreements.

SHORT-TERM INVESTMENTS

3 Months Ended

Mar. 31, 2024

Investments, All Other Investments [Abstract]

SHORT-TERM INVESTMENTS

NOTE 4 - SHORT-TERM INVESTMENTS

As of March 31, 2024, the Company’s available-for-sale investments by type, consisted of the following:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Credit Losses		Fair Value
U.S. Government Agency bonds	$	7,940	$	—	$	(4	)	$	—	$	7,936
U.S. Treasury bonds		7,633		—		(3	)		—		7,630
Total	$	15,573	$	—	$	(7	)	$	—	$	15,566

As of March 31, 2024, all available-for-sale securities consisted of investments that mature within one year.

Condensed Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Treasury Stock, Common [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 22	$ 9	$ (433)	$ 154,401	$ 2	$ (189,784)	$ (35,783)
Balance, shares at Dec. 31, 2022	22,094,889	9,126,726	(433,333)
Stock compensation				227			227
Issuance of common shares upon the closing of the initial public offering, net of offering costs		$ 3		12,629			12,632
Issuance of common shares upon the closing of the initial public offering, net of offering costs, shares		2,653,000
Issuance of common shares upon conversion of preferred stock	$ (22)	$ 8		14
Issuance of common shares upon conversion of preferred stock, shares	(22,094,889)	8,355,610
Issuance of common shares upon conversion of convertible notes payable, accrued interest and loan fees		$ 5		29,891			29,896
Issuance of common shares upon conversion of convertible notes payable, accrued interest and loan fees, shares		4,134,367
Issuance of common shares upon conversion of preferred stock dividends payable				3,443		(3,443)
Issuance of common shares upon conversion of preferred stock dividends payable, shares		272,101
Fair value of vested restricted stock units				198			198
Cost of stock option repricing				2,606			2,606
Reclassification of warrant liabilities upon the closing of the initial public offering				169			169
Fair value of warrants issued in connection with the the conversion of convertible notes payable				3,110			3,110
Shares issued upon cashless exercise of stock warrant
Shares issued upon cashless exercise of stock warrant, shares		11,666
Net loss						(10,364)	(10,364)
Balance at Mar. 31, 2023		$ 25	$ (433)	206,688	2	(203,591)	2,691
Balance, shares at Mar. 31, 2023		24,553,470	(433,333)
Balance at Dec. 31, 2023		$ 27	$ (433)	241,389	14	(221,524)	19,473
Balance, shares at Dec. 31, 2023		26,788,986	(433,333)
Stock compensation				1,489			1,489
Fair value of vested restricted stock units				989			989
Net loss						(7,850)	(7,850)
Unrealized loss on short-term investments					(19)		(19)
Fair value of vested restricted stock units , shares		131,267
Issuance of common shares upon exercise of stock warrants				688			$ 688
Issuance of common shares upon exercise of stock warrants, shares		76,487
Balance at Mar. 31, 2024		$ 27	$ (433)	$ 244,869	$ (5)	$ (229,374)	$ 15,084
Balance, shares at Mar. 31, 2024		26,996,740	(433,333)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 8	$ 170
Unrealized gains on short term investments, net of tax	19
Money Market Funds [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash	2,988		$ 7,924
License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 8

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

SCHEDULE OF FINANCIAL ASSETS AND LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Cash equivalents and Short-term investments	$ 18,554
US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
US Government Agency bonds	7,936
US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
US Government Agency bonds	7,630
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	2,988
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Cash equivalents and Short-term investments	2,988
Fair Value, Inputs, Level 1 [Member] \| US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
US Government Agency bonds
Fair Value, Inputs, Level 1 [Member] \| US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
US Government Agency bonds
Fair Value, Inputs, Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	2,988
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Cash equivalents and Short-term investments	15,566
Fair Value, Inputs, Level 2 [Member] \| US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
US Government Agency bonds	7,936
Fair Value, Inputs, Level 2 [Member] \| US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
US Government Agency bonds	7,630
Fair Value, Inputs, Level 2 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Cash equivalents and Short-term investments
Fair Value, Inputs, Level 3 [Member] \| US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
US Government Agency bonds
Fair Value, Inputs, Level 3 [Member] \| US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
US Government Agency bonds
Fair Value, Inputs, Level 3 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds

SCHEDULE OF WARRANTS ACTIVITY (Details)	3 Months Ended
SCHEDULE OF WARRANTS ACTIVITY (Details)	Mar. 31, 2024 $ / shares shares
Number of warrant shares, beginning \| shares	512,759
Weighted average exercise price, beginning	$ 7.14
Number of warrant shares, granted \| shares
Exercise price range per share, granted
Weighted average exercise price, granted
Number of warrant shares, cancelled \| shares
Exercise price range per share, cancelled
Weighted average exercise price, cancelled
Number of warrant shares, exercised \| shares	(76,487)
Weighted average exercise price, exercised	$ 9.00
Number of warrant shares, expired \| shares	(38,297)
Weighted average exercise price, expired	$ 9.15
Number of warrant shares, ending \| shares	397,975
Weighted average exercise price, ending	$ 6.59
Number of warrant shares, exercisable \| shares	397,975
Weighted average exercise price, exercisable	$ 6.59
Minimum [Member]
Exercise price range range per share, beginning	3.00
Exercise price range per share, exercised	9.00
Exercise price range per share, expired	9.00
Exercise price range per share, ending	3.00
Exercise price range per share, exercisable	3.00
Maximum [Member]
Exercise price range range per share, beginning	10.50
Exercise price range per share, expired	10.50
Exercise price range per share, ending	9.00
Exercise price range per share, exercisable	$ 9.00

SUBSEQUENT EVENTS (Details Narrative) $ in Thousands	May 15, 2024 USD ($)
Employee [Member] \| Subsequent Event [Member]
Accrued compensation	$ 1,024

Condensed Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net loss	$ (7,850)	$ (10,364)
Other comprehensive loss:
Net unrealized loss on short-term investments	(19)
Comprehensive loss	$ (7,869)	$ (10,364)

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

ACCRUED PAYROLL AND PAYROLL TAXES (Details Narrative) - USD ($) $ in Thousands	May 15, 2024	Mar. 31, 2024	Dec. 31, 2023
Accrued payroll and payroll taxes current		$ 1,908	$ 2,117
Payroll tax liability		$ 321	$ 321
Employee [Member] \| Subsequent Event [Member]
Accrued compensation	$ 1,024

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2024

Subsequent Events

SUBSEQUENT EVENTS

NOTE 10 - SUBSEQUENT EVENTS

Subsequent to March 31, 2024, the Company repaid $1,024 of past due accrued payroll related amounts owed to an employee (see Note 6).

FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES

NOTE 3 - FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES

The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis:

	Fair Value Measurements as of March 31, 2024, Using:
	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	2,988	$	—	$	—	$	2,988
Short-term investments:
U.S. Government Agency bonds		—		7,936		—		7,936
U.S. Treasury bonds		—		7,630		—		7,630
	$	2,988	$	15,566	$	—	$	18,554

The underlying securities in the money market funds held by the Company are all government backed securities.

Valuation of cash equivalents and short-term investments

Cash equivalents consisted of money market funds at March 31, 2024. Money market funds were valued by the Company using quoted prices in active markets for identical securities, which represent a Level 1 measurement within the fair value hierarchy. U.S. Government Agency bonds and U.S. Treasury bonds are government backed securities representing a Level 2 measurement within the fair value hierarchy.

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,574,218	5,419,391
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,118,920	4,201,019
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	397,975	1,034,979
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	57,323	113,500
Stock Warrants Issuable Upon Conversion of Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		69,893

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2024	May 05, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-41599
Entity Registrant Name	GENELUX CORPORATION
Entity Central Index Key	0001231457
Entity Tax Identification Number	77-0583529
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2625 Townsgate Road
Entity Address, Address Line Two	Suite 230
Entity Address, City or Town	Westlake Village
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91361
City Area Code	(805)
Local Phone Number	267-9889
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	GNLX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,996,740

SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS (Details)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 6.00
Options outstanding number of outstanding \| shares	3,878,133
Options outstanding average remaining contractual life	4 years 3 months 18 days
Options outstaning weighted average exercise price	$ 6.00
Options exercisable number of outstanding \| shares	3,763,653
Options exercisable average remaining contractual life	4 years 2 months 12 days
Options exercisable weighted average exercise price	$ 6.00
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 10.50
Options outstanding number of outstanding \| shares	90,099
Options outstanding average remaining contractual life	1 year 9 months 10 days
Options outstaning weighted average exercise price	$ 9.52
Options exercisable number of outstanding \| shares	90,099
Options exercisable average remaining contractual life	1 year 9 months 10 days
Options exercisable weighted average exercise price	$ 9.52
Range of exercise prices, lower limit	6.01
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 24.75
Options outstanding number of outstanding \| shares	1,150,688
Options outstanding average remaining contractual life	9 years 5 months 12 days
Options outstaning weighted average exercise price	$ 22.26
Options exercisable number of outstanding \| shares	1,408
Options exercisable average remaining contractual life	9 years 5 months 8 days
Options exercisable weighted average exercise price	$ 22.40
Range of exercise prices, lower limit	10.51
Exercise Price Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise prices, upper limit	$ 24.75
Options outstanding number of outstanding \| shares	5,118,920
Options outstanding average remaining contractual life	5 years 5 months 4 days
Options outstaning weighted average exercise price	$ 9.76
Options exercisable number of outstanding \| shares	3,855,160
Options exercisable average remaining contractual life	4 years 1 month 20 days
Options exercisable weighted average exercise price	$ 6.09
Range of exercise prices, lower limit	$ 6.00

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 4,061	$ 9,418
Short-term investments	15,566	13,773
Prepaid expenses and other current assets	1,577	1,012
Total Current Assets	21,204	24,203
Property and equipment, net	1,116	1,170
Right of use assets	2,264	2,428
Other assets	92	92
Total Other Assets	3,472	3,690
TOTAL ASSETS	24,676	27,893
Current Liabilities
Accounts payable and accrued expenses	5,313	3,784
Accrued payroll and payroll taxes	1,908	2,117
Lease liabilities, current portion	584	653
Total Current Liabilities	7,805	6,554
Lease liabilities, long-term portion	1,787	1,866
Total Liabilities	9,592	8,420
Shareholders’ Equity
Preferred stock, par value $0.001, 10,000,000 shares authorized; no shares issued and outstanding, respectively;
Common stock, par value $0.001, 200,000,000 shares authorized; 26,996,740 and 26,788,986 shares issued and outstanding, respectively	27	27
Treasury stock, 433,333 shares, at cost	(433)	(433)
Additional paid-in capital	244,869	241,389
Accumulated other comprehensive income (loss)	(5)	14
Accumulated deficit	(229,374)	(221,524)
Total Shareholders’ Equity	15,084	19,473
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 24,676	$ 27,893